CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Junshi Biosciences Doses First Patient in Phase 3 Trial of JS207-JS007 for Advanced Liver Cancer

By Public Technologies
  • Junshi Biosciences completed first-patient dosing in a Phase 3 trial of JS207 with JS007 on Oct. 29, 2026.
  • The trial compares the combination with toripalimab plus bevacizumab as a first-line treatment for advanced hepatocellular carcinoma.
  • Planned enrollment is 560 patients, with overall survival and progression-free survival as primary endpoints.
  • Phase 2 results were presented at the European Society for Medical Oncology Congress in October 2026.
  • Those results showed strong anti-tumor activity; the combination was well tolerated.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Junshi Biosciences Co. Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610290704PRIMZONEFULLFEED9856020) on October 29, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk